BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...export pump (BSEP) deficiency who had responded to maralixibat treatment in the open-label Phase II INDIGO...
BioCentury | Jun 29, 2018
Clinical News

Gemphire's gemcabene meets in Phase IIb for severe hypertriglyceridemia

...Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported data from the Phase IIb INDIGO-1 trial to treat severe hypertriglyceridemia...
BioCentury | Apr 20, 2018
Clinical News

NewLink re-evaluating Phase III plans for indoximod combo in melanoma

NewLink Genetics Corp. (NASDAQ:NLNK) said it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat unresectable or...
BioCentury | Apr 16, 2018
Clinical News

NewLink re-evaluating Phase III plans for indoximod combo

NewLink Genetics Corp. (NASDAQ:NLNK) said Sunday that it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat...
BioCentury | Aug 21, 2017
Company News

Shire CFO stepping down

...Poulton will leave the company at year end to become CFO at plant microbiome start-up Indigo...
BioCentury | Aug 11, 2017
Clinical News

Gemphire reports Phase IIb data of gemcabene for hypercholesterolemia

...a total of 12 weeks (see BioCentury, July 17 ). Data from the Phase IIb INDIGO-1...
BioCentury | Aug 7, 2017
Clinical News

Gemphire sinks on Phase IIb gemcabene data in hypercholesterolemia

...from competitors in the cardiovascular space, Golden told the call. Data from the Phase IIb INDIGO-1...
BioCentury | Jul 28, 2017
Company News

Mitsubishi acquiring NeuroDerm

...a subcutaneous belt pump to treat Parkinson's disease. The candidate is in the Phase III iNDiGO...
...the primary endpoint of reduced daily "off" time in the Phase IIa Trial 006 study. iNDiGO...
BioCentury | Jul 24, 2017
Company News

Mitsubishi Tanabe acquiring NeuroDerm

...a subcutaneous belt pump to treat Parkinson's disease. The candidate is in the Phase III iNDiGO...
...the primary endpoint of reduced daily "off" time in the Phase IIa Trial 006 study. iNDiGO...
BioCentury | Mar 3, 2017
Clinical News

ND0612H: Preliminary Ph IIa Trial 006 data

...reactions reported as the most common adverse event. In December, NeuroDerm suspended the Phase III iNDiGO...
...order to submit a reduced data package under EMA’s centralized procedure. Instead, NeuroDerm will restart iNDiGO...
...arm and new endpoints, including a response analysis. The company plans to use data from iNDiGO...
Items per page:
1 - 10 of 28
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...export pump (BSEP) deficiency who had responded to maralixibat treatment in the open-label Phase II INDIGO...
BioCentury | Jun 29, 2018
Clinical News

Gemphire's gemcabene meets in Phase IIb for severe hypertriglyceridemia

...Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported data from the Phase IIb INDIGO-1 trial to treat severe hypertriglyceridemia...
BioCentury | Apr 20, 2018
Clinical News

NewLink re-evaluating Phase III plans for indoximod combo in melanoma

NewLink Genetics Corp. (NASDAQ:NLNK) said it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat unresectable or...
BioCentury | Apr 16, 2018
Clinical News

NewLink re-evaluating Phase III plans for indoximod combo

NewLink Genetics Corp. (NASDAQ:NLNK) said Sunday that it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat...
BioCentury | Aug 21, 2017
Company News

Shire CFO stepping down

...Poulton will leave the company at year end to become CFO at plant microbiome start-up Indigo...
BioCentury | Aug 11, 2017
Clinical News

Gemphire reports Phase IIb data of gemcabene for hypercholesterolemia

...a total of 12 weeks (see BioCentury, July 17 ). Data from the Phase IIb INDIGO-1...
BioCentury | Aug 7, 2017
Clinical News

Gemphire sinks on Phase IIb gemcabene data in hypercholesterolemia

...from competitors in the cardiovascular space, Golden told the call. Data from the Phase IIb INDIGO-1...
BioCentury | Jul 28, 2017
Company News

Mitsubishi acquiring NeuroDerm

...a subcutaneous belt pump to treat Parkinson's disease. The candidate is in the Phase III iNDiGO...
...the primary endpoint of reduced daily "off" time in the Phase IIa Trial 006 study. iNDiGO...
BioCentury | Jul 24, 2017
Company News

Mitsubishi Tanabe acquiring NeuroDerm

...a subcutaneous belt pump to treat Parkinson's disease. The candidate is in the Phase III iNDiGO...
...the primary endpoint of reduced daily "off" time in the Phase IIa Trial 006 study. iNDiGO...
BioCentury | Mar 3, 2017
Clinical News

ND0612H: Preliminary Ph IIa Trial 006 data

...reactions reported as the most common adverse event. In December, NeuroDerm suspended the Phase III iNDiGO...
...order to submit a reduced data package under EMA’s centralized procedure. Instead, NeuroDerm will restart iNDiGO...
...arm and new endpoints, including a response analysis. The company plans to use data from iNDiGO...
Items per page:
1 - 10 of 28